Skip to main
IMTX
IMTX logo

Immatics NV (IMTX) Stock Forecast & Price Target

Immatics NV (IMTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immatics NV is making significant advancements in T-cell redirecting immunotherapies, particularly with its anzu-cel asset, which targets a high-unmet need market for metastatic cancers, presenting a substantial revenue opportunity estimated at $2 billion in the U.S. The company's innovative ACTengine platform enhances treatment logistics and has demonstrated strong manufacturing efficiency with a 98% success rate in Phase 1b, promising quicker product availability. Furthermore, the positive early data and the support from FDA's RMAT designation position Immatics favorably for potential success in its ongoing pivotal SUPRAME study, reinforcing a positive outlook for the company's financial performance.

Bears say

Immatics NV faces a negative outlook primarily due to underwhelming clinical data, specifically the 11% Overall Response Rate (ORR) and 56% Disease Control Rate (DCR) observed in Brenetafusp during ASCO '24, which may lead to downward revisions in risk-adjusted projections. The company is also exposed to multiple risks, including potential R&D setbacks, regulatory challenges, and the emergence of new competitors, which could further impact product sales adversely. Additionally, a downside scenario predicts a valuation drop to approximately $3 per share if critical milestones, such as those related to the SUPRAME study and early pipeline developments, are not met.

Immatics NV (IMTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immatics NV (IMTX) Forecast

Analysts have given Immatics NV (IMTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Immatics NV (IMTX) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immatics NV (IMTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.